glp-1 vs sglt2 diabetes Receptor Agonist Therapy With and Without Inhibitors in Patients With Type 2 GLP-1 Receptor Agonists and SGLT2

Effects of semaglutide on mortality, cardiovascular, and kidney outcomes: systematic review and meta-analysis

People with severe kidney or liver disease may require caution or alternative treatments, and their use should be discussed with healthcare providers

Immix Biopharma has hired former Republican House staffers Tim Costa and Luke Nickless at Continental Strategy to lobby on FDA issues

Systemic investigation of promoter-wide methylome and genome variations in gout

(C) Cells given 0.4 mM palmitic acid were treated with 100 nM Ex-4 in the absence or presence of 10 mM nicotinamide (NAM) or 10 M compound C (CC) for 24 hours